Pharmacist (state examination), Martin Luther University Halle, Germany
Liver fibrosis is responsible for a high morbidity because of the development of cirrhosis and hepatocellular carcinoma. Due to the high prevalence and mortality of hepatic fibrosis and the necessity of repetitive evaluation of disease progression, my project is about the development and physicochemical characterization as well as in vitro cell culture testing of targeted liposomes for non-invasive diagnostic molecular imaging for an early diagnosis and to improve management strategies of this chronic fibro-proliferative disease.
Pharmacist, Università degli Studi della Calabria, Italy
Pharmacist (state examination), Friedrich-Schiller-University Jena, Germany
My research is about the development of a novel liposomal depot system for the sustained drug delivery. Using depot system the amount of injections could be decreased to a minimum and therefore we can improve the compliance of patients and with this we can contribute to an increased quality of life.
MSc ETH Pharm. Sc, ETH Zurich, Switzerland
Liver fibrosis is the wound-healing response to chronic hepatic insults, often leading to the loss of organ function. It is characterized by the excessive deposition of scar tissue, a process driven by activated hepatic stellate cells (HSC). The broader aim of our research is to assess the impact of lipid-based therapeutics on extracellular vesicles isolated from hepatic cell lines, used as an in vitro model for the progression of liver fibrosis.
This project is in collaboration with Dr. Gregor Fuhrmann, at the Helmholtz-Institute for Pharmaceutical Sciences Saarland (HIPS), Germany.
M. Sc. In Molecular Life Sciences with specifications in Biochemistry and chemical Biology, University of Bern, Switzerland
PhD, Sapienza University of Rome, Italy
Since the beginning of my studies, I have been interested in working at the interface of chemistry and biology. Through the years, I investigated the biophysical characteristics of bio-membrane; their interaction with drugs, proteins, and fluorescent probes. I had the chance to characterize lipid formulations for different purposes and use them as drug carriers systems. My research is now focused predominantly on the development of a lipid based gel delivery systems. These materials exhibit a unique combination of properties: they are biocompatible and able to entrap molecules of various polarities and sizes; they have a soft-gel consistency that enables them to act as depot and thus enhance the epithelium drug permeability achieving exquisite spatial, temporal and dosage control when administered topically or subcutaneously.
Pharmacist (state examination), Ludwig-Maximilians-University Munich, Germany
B.Sc. Management and Technology, Technical University Munich, Germany
My research studies the microfluidic assembly of siRNA embedded nanoparticles to treat allergic asthma. It is in cooperation with Prof O. Merkel at the department of pharmaceutical technology at the LMU Munich.
My everyday motivation and the foundation for my research is my belief in helping patients by tackling scientific problems. Furthermore, the PhD is a great opportunity to promote a project independently.
M.Sc. in Industrial Pharmacy & B.E. in Chemical Technology at University of Ljubljana
By transplanting composite grafts such as faces or limbs, vascularised composite transplantation (VCA) has a potential to radically improve patients’ lives. A major challenge is the need for life-long systemic immunomodulatory therapy for these patients, which leads to their shorter life expectancy. My research focuses on building depot delivery systems that bring the drug in the right doses where it’s needed, without doing harm to the other parts of the body. Using biocompatible phospholipids and gels to build these delivery systems, the VCA patients could live longer and with less frequent drug administration.